Loading patent…
AssigneeTrubion Pharmaceuticals, Inc.
InventorsJeffrey A Ledbetter, Martha Hayden-Ledbetter
Estimating the term…
Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto MHC molecules. T cells specific for the peptide antigens are activated, leading to an enhanced immune response. The vaccine may comprise antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid encoding antigen(s) linked to a domain that binds at least one receptor. A preferred embodiment of the invention targets HIV-1 env antigen to the CD40 receptor, resulting in delivery of antigen to CD40 positive cells, and selective activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.
An antigenic polypeptide comprising an antigen domain and a receptor-binding domain, said antigen domain comprising HIV-1 gp160 or a portion thereof and said receptor-binding domain comprising a CD40-binding polypeptide,
An antigenic polypeptide comprising an antigen domain and a receptor-binding domain, said antigen domain comprising HIV-1 gp160 or a portion of HIV-1 gp160, said receptor-binding domain comprising at least a portion of a CD154 polypeptide capable of binding to CD40.
Dependencies are inferred from the claim text.